THE DISCONNECT BETWEEN FUNDING DECISIONS OF CANCER DRUGS AND COMPANION DIAGNOSTIC TESTS IN CANADA

Author(s)

Poinas A, Wyatt G
Wyatt Health Management, Oakville, ON, Canada

OBJECTIVES:

More and more pharmaceuticals receive indications that require the use of companion diagnostic tests to identify subgroups of patients who would benefit from the therapy. Many mutations have been identified in cancer and the choice of treatment frequently depends on the result of a specific companion diagnostic test. In Canada, the pan Canadian Oncology Drug Review (pCODR) assesses cancer drugs based on clinical evidence, cost-effectiveness and patient input, to make recommendations to Canada’s provinces in guiding their funding decisions.The objective of this study is to determine how pCODR assesses drugs that require a companion diagnostic. METHODS: All pCODR recommendations as of were reviewed and those involving the use of a companion diagnostic were identified. Analysis of these recommendations was conducted to determine how companion diagnostic tests accompanying cancer drugs were reviewed by pCODR. RESULTS: pCODR has received 52 submissions since its inception and 39 recommendations have been issued. Of these recommendations, 9 involved the use of a companion diagnostic test. Both positive and negative comments around companion diagnostic tests were found among the pCODR recommendations. (Results will be tabulated) CONCLUSIONS: pCODR recommendations are dedicated to cancer drugs.  However for those drugs requiring a companion diagnostic, pCODR also looks at the information related to these tests, e.g. costs and utility. However, there is no submission process for companion diagnostic tests at pCODR. Consequently, there is opportunity for inconsistency among the pCODR recommendations for cancer drugs and associated companion diagnostic tests.

Conference/Value in Health Info

2015-05, ISPOR 2015, Philadelphia, PA, USA

Value in Health, Vol. 18, No. 3 (May 2015)

Code

PCN134

Topic

Epidemiology & Public Health, Health Policy & Regulatory, Organizational Practices

Topic Subcategory

Academic & Educational, Disease Classification & Coding, Pricing Policy & Schemes

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×